Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Argenta and Genentech extend deal
November 2007
SHARING OPTIONS:

HARLOW, U.K.—Argenta Discovery Ltd. has extended its integrated contract drug discovery agreement with Genentech Inc. for another two-year period. The first collaboration project under the agreement was announced in December 2005, and a second project was entered into in March 2007. The two programs utilize Argenta's expertise in computer-aided drug design, medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
Dr. Christopher Ashton, Argenta's CEO, says, "We are delighted that Genentech has chosen to extend the collaboration for another two years. The two projects have made excellent progress and a good working relationship has been established between both teams of scientists over the past two years. We believe this extension illustrates Argenta's key strengths and continued commitment to deliver high-quality, time- and cost-effective integrated drug discovery services and expertise."
Financial terms of the deal were not disclosed. The agreement provides further options to expand the relationship.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.